A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small amounts of common food allergens.
Omalizumab outperforms oral immunotherapy in treating multi-food allergy
- Post author:admin
- Post published:March 2, 2025
- Post category:uncategorized